

## Bringing the Cleanroom to Standard: Cytotoxic Drug Preparation in Eldoret, Kenya



Kya Norby, PharmD, RPh Bristol-Myers Squibb Foundation, Princeton Pike, NJ USA

## OPTIMIZATION OPPORTUNITY

Moi Teaching and Referral Hospital (MTRH) in Eldoret, Kenya serves a population of ~24 million from western Kenya and neighboring countries.<sup>1</sup> The chemotherapy pharmacy consists of a cleanroom, anteroom, storage area, and pulley system to transport prepared chemotherapy to the administration area on the floor below. In September 2018, the pharmacy was facing a number of challenges.

- When constructed, a door was not built between the anteroom, where gowning and garbing occurs, and the cleanroom, where chemotherapy preparation occurs.
- Non-pharmacy personnel were entering the cleanroom without gown and garb to deliver chemotherapy orders.
- Dirt was visible on the cleanroom floor and walls.

These challenges indicated there was opportunity for quality improvement efforts to increase the pharmacy's compliance with best practices for cleanroom operations.

## OBJECTIVE

The primary objective was to improve the compliance of a cytotoxic drug preparation cleanroom in Eldoret, Kenya with best practice standards.

## METHODS

- Support and oversight from pharmacy leadership was obtained.
- A needs assessment was conducted by pharmacy leadership, staff, and the author, including observation of daily chemotherapy pharmacy activities.
- Applicable standard operating procedures (SOPs) were gathered and reviewed. Additional SOPs were developed as needed.
- Quality improvement interventions were developed and implemented to address:
  - o Pharmacy cleanliness
  - o Anteroom-cleanroom configuration
  - Sterile preparation practices

## RESULTS

## Pharmacy leadership support and oversight Needs assessment Quality and observation Improvemen Interventions Standard operating

**NEXT STEPS** 

• Enforce proper cleanroom operations and cleaning techniques

Provide initial and refresher training for new and seasoned staff

Monitor completion of checklists, schedules, and logs

Advocate for funding for pending interventions

Chemotherapy pharmacy leadership will:

Maintain SOPs at regular intervals

procedures

## Completed

- In-depth cleaning
- Six new/updated SOPs
- Cleaning checklist, schedule,
- Application of floor demarcation
- Sterile in-hood use of alcohol and gauze
- Training on IV fluid reduction by syringe


## Pending

- Sliding window
- Replace all cardboard
- pulley system

- and log

- for pass-through
- with plastic containers
- 2-cart system for

# Cleanroom



Storage area

Figure 3. Chemotherapy pharmacy layout

## LIMITATIONS

- Cleanroom-anteroom construction
- Limited medical equipment and technology
- Lack of sterile compounding and cytotoxic preparation certifications for pharmacy personnel
- Lack of advanced-degree pharmacy training
- Limited pharmacy personnel
- Hospital resources and financing
- Hospital leadership's priorities

## CONCLUSIONS

While chemotherapy pharmacies in Kenya are not held to standards like the USP 800, it is of benefit to patient safety and health outcomes to comply with best practices.

Although the MTRH pharmacy may not be able to meet all standards currently, there was opportunity to make several manageable changes that increased compliance with best practices. The pharmacy also has a plan for additional changes to advocate for to hospital leadership.

This project highlighted the pharmacy's strengths in creative problem-solving and maintaining a continuous quality improvement mindset. These strengths will serve them well in continuing to improve patient care.

## **ACKNOWLEDGEMENTS**

Special thanks to the preceptors who helped facilitate and support this global health opportunity.

John Damonti, MSW Phangisile Mtshali

Michael Toscani, PharmD Evelyn Hermes-DeSantis, PharmD

Patricia Doykos, PhD Priscilla Ko, PharmD

Joseph Barone, PharmD

## REFERENCES

Partners. AMPATH Kenya. https://www.ampathkenya.org/\_\_\_\_ partners. Published 2019. Accessed March 4, 2019.

### **AUTHOR CONTACT INFORMATION**

Kya Norby kya.norby@bms.com

The author is affiliated with the Rutgers Institute for Pharmaceutical Industry Fellowship Program and is a paid employee of Rutgers, the State University of New Jersey

DISCLOSURE